atorvastatin / Generic mfg. - LARVOL DELTA

The Disparate Effect of Statins on eGFR in Systemic Lupus Erythematosus (ACR Convergence 2026) - "The 2010 atorvastatin (LAPS) trial found no significant eGFR change in 200 SLE patients; however, patients were followed for only two years... Statins slowed eGFR decline in non- lupus nephritis SLE patients which align with findings from general CKD populations. However, statins showed no GFR benefit in lupus nephritis patients. These findings suggest statins may have disparate effects in SLE, depending on the presence of lupus nephritis."

Cardiovascular • Chronic Kidney Disease • Diabetes • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease • Systemic Lupus Erythematosus

Clinical Outcomes of an ApoE Genotype-Guided Lipid-Lowering Strategy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. (PubMed, Pharmgenomics Pers Med) - "The control group (n=120) received standard atorvastatin therapy. An ApoE genotype-guided lipid-lowering escalation strategy, in which E4 carriers-who typically respond suboptimally to statin monotherapy and carry a higher residual risk-received add-on PCSK9-inhibitor (evolocumab) therapy, was associated with improved clinical efficacy, cardiac function, and lipid control in ACS patients after PCI. Because the study group received more intensive lipid-lowering therapy, the observed benefits most plausibly reflect the greater treatment intensity achieved through genotype-directed escalation rather than the act of genotyping alone, and require confirmation in prospective randomized trials with longer follow-up."

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Metabolic Disorders • APOE

Real-world comparative outcomes of evolocumab versus high-intensity statin for primary prevention (ESC 2026) - "Cohorts required initiation of either high-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) or evolocumab; each cohort excluded use of the comparator lipid-lowering agent and alirocumab. In this large propensity score–matched analysis of primary prevention patients with ASCVD risk factors, evolocumab was associated with significantly lower all-cause mortality, acute heart failure, and hospitalization compared with high-intensity statin therapy. However, evolocumab users demonstrated higher rates of acute MI and persistent LDL-C elevation. These findings suggest potential complementary roles for PCSK9 inhibitors in primary prevention but warrant prospective validation."

Clinical • Real-world • Real-world evidence • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Myocardial Infarction

Atorvastatin potentiates the efficacy of gemcitabine in diabetic pancreatic cancer via remodeling the tumor immune microenvironment and attenuating vascular endothelial. (PubMed, J Pharm Pharmacol) - "These findings support the potential of atorvastatin plays a crucial role in suppressing vascular endothelial inflammation and reprogramming immune cell infiltration, thereby potentiating the efficacy of gemcitabine in diabetic pancreatic cancer."

Journal • Oncology • Pancreatic Cancer • Solid Tumor • CD4 • CD8 • FCER1G • NUSAP1

Inducing oxidative stress by targeting the cholesterol biosynthesis pathway augments the efficacy of bortezomib in multiple myeloma. (PubMed, Free Radic Biol Med) - "Proteasome inhibitors, particularly bortezomib (BTZ) which induces oxidative stress, remain the cornerstone of multiple myeloma (MM) therapy. Decreasing 7-DHC production by disrupting SREBF2 activation or treating with atorvastatin impaired the cellular ROS detoxification capacity and enhanced BTZ-induced cytotoxicity. Collectively, our findings identify that MM cells resist therapy-induced ROS by accumulating 7-DHC through activation of cholesterol biosynthesis, and provide preclinical evidence for repurposing statins to augment the efficacy of BTZ therapy."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • FLOT1 • FOXO3 • SREBF2

RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque Remodeling (clinicaltrials.gov) - P4 | N=120 | Not yet recruiting | Sponsor: Keqiang Zhao

New P4 trial • Atherosclerosis • Cardiovascular

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: University of Colorado, Denver

New P2 trial • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Immune Modulation • Immunology • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Effect of loading dose atorvastatin on postoperative cardiovascular events in elderly patients with acute myocardial infarction undergoing percutaneous coronary intervention. (PubMed, Am J Transl Res) - "Loading-dose atorvastatin can improve cardiac function, regulate lipid metabolism, suppress inflammatory responses, and reduce the incidence of short-term MACE in elderly AMI patients after PCI, while demonstrating good safety and clinical application value."

Journal • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • Myocardial Infarction • CRP

GC-MS profiling, network pharmacology, and computational investigations of canola phytochemicals as potential cardioprotective agents. (PubMed, In Silico Pharmacol) - "Hydrogen bond and π-π stacking with the amino acid residue forms the oleic acid-C-terminal domain of HSF1 complex, that is stable and exhibits highest binding affinity of - 7.9 kcal/mol, higher than that of standard drug atorvastatin-C-terminal domain of human heat shock factor 1 (HSF1) complex with affinity score of - 7.8 kcal/mol...The present study is the first in its ability to enumerate a range of potentially pharmacologically active compounds/bioactive compounds in canola variety seed/seed oil by GC-MS analysis and enunciates a novel nutraceutical approach for the prevention of CVD. The online version contains supplementary material available at https://doi.org/10.1007/s40203-026-00744-y."

Journal • Cardiovascular • EGFR • HSF1

Therapeutic Efficacy of Prosopis farcta versus Scrophularia striata Ethanolic Extracts in Atherosclerosis: Do They Compare Favorably with Atorvastatin in an Experimental Model? (PubMed, Endocr Metab Immune Disord Drug Targets) - "Prosopis farcta (50 mg/kg) demonstrated significant hypolipidemic and antiatherogenic effects comparable to atorvastatin, while Scrophularia striata showed paradoxical adverse effects. These findings suggest that Prosopis farcta warrants further investigation as a potential herbal candidate for the management of atherosclerosis. However, clinical trials are needed to confirm its efficacy and safety in humans."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • Pain • PON1

A flow cytometry-based assay system for the in vitro screening of anti-steatotic compounds. (PubMed, In Vitro Model) - "The assay was validated using known anti-steatotic drugs, where Saroglitazar, Pioglitazone, Empagliflozin, and Atorvastatin significantly reduced lipid accumulation in HepG2 cells. The present flow cytometry assay is a human cell-based and animal-free system that offers a sensitive, accurate, and high-throughput platform for evaluating anti-steatotic compounds, with clear advantages over conventional methods for early-stage drug discovery. The online version contains supplementary material available at https://doi.org/10.1007/s44164-026-00110-4."

Journal • Preclinical • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease

Statin use and 28-day survival in critically ill patients with non-acute myocardial infarction cardiogenic shock: A retrospective cohort study accounting for treatment timing. (PubMed, Medicine (Baltimore)) - "Statin exposure was ascertained from medication records that included atorvastatin and other statin agents...The apparent survival advantage associated with conventional time-fixed statin exposure was not reproduced after treatment timing was addressed. These findings do not support an independent 28-day survival benefit from statin administration within the 1st 24 hours of ICU admission and highlight the potential influence of immortal-time, treatment-selection, and co-treatment biases."

Journal • Retrospective data • Cardiovascular • Critical care • Myocardial Infarction

Pathophysiological modulations by Trimad, a polyherbal formulation, in a rat model of high-fat diet-induced obesity. (PubMed, J Ayurveda Integr Med) - "Trimad effectively ameliorated HFD-induced obesity and demonstrated strong anti-obesity potential."

Journal • Preclinical • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity

Atorvastatin-007: LDL-c Level Variability and Trained Immunity (clinicaltrials.gov) - P=N/A | N=11 | Completed | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting ➔ Completed

Trial completion

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Cardiovascular • Esophageal Cancer • Heart Failure • Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Real-world patterns in lipid profile testing and lipid-lowering therapy in hospitalized patients: The Jurasz Lipid Study. (PubMed, Int J Cardiol Cardiovasc Risk Prev) - "Statin monotherapy remained the standard of care, with atorvastatin and rosuvastatin being the most frequently used agents. Statin monotherapy remained the cornerstone of LLT. Statin with ezetimibe was the most common therapeutic combination."

Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Pediatrics

Evaluation of the Efficacy, Safety, and Economics of Generic and Branded Atorvastatin: A Real-World Study (ChiCTR) - P=N/A | N=1256 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University

New trial • Real-world evidence • Atherosclerosis • Cardiovascular • CNS Disorders • Coronary Artery Disease • Dyslipidemia • Heart Failure • Metabolic Disorders • Vascular Neurology

Statin use and risk of remote seizure after first new onset status epilepticus. (PubMed, Epilepsia) - "The overall risk of RS was moderate and temporally confined within a few years from the index event. Statin exposure was associated with a lower incidence of RS. Our findings expand knowledge regarding a possible antiepileptogenic role of statins after SE and support further studies in this field."

Journal • CNS Disorders • Epilepsy

Protective Effects of Policosanol and Atorvastatin Co-Supplementation Against High-Cholesterol and High-Galactose Diet-Induced Metabolic and Organ Dysfunction in Zebrafish. (PubMed, Int J Mol Sci) - "Also, Poli and Poli+Ator substantially minimize HCHG-triggered oxidative stress in reproductive organs, enhance spermatozoa count in the testis and substantially improve the embryo-producing ability of zebrafish. The study outlines the beneficial effect of Poli and Poli+Ator in mitigating HCHG-induced dyslipidemia, organ damage, and reproductive health."

Journal • Dyslipidemia • Fibrosis • Immunology • Metabolic Disorders • IL6

Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up. (PubMed, Scand J Prim Health Care) - "During a period of increasing pharmacotherapeutic opportunities, this study, conducted in everyday clinical practice suggests that common lipid-lowering medications (atorvastatin and rosuvastatin) are most frequently used for primary health care patients, and are associated with a significant decrease in LDL-C levels. A greater decrease was observed among patients with higher baseline LDL-C values. Despite decreases in LDL-C, this study suggests that the gap remains between guideline-recommended treatment targets and achieved LDL-C levels."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Hypertension • Hypotension • Metabolic Disorders

Lysophosphatidylcholine-induced macrophage polarization imbalance and functional dysregulation in immune thrombocytopenia. (PubMed, Chin Med J (Engl)) - "LPC (16:0/0:0) drives ITP pathogenesis by reprogramming macrophage metabolism and function, promoting inflammation and platelet destruction. The DXM-AT combination exerts synergistic therapeutic effects by complementary targeting of metabolic and immune pathways in the LPC-driven pathogenic axis, effectively restoring immune homeostasis."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Inflammation • Metabolic Disorders • Thrombocytopenia • Thrombocytopenic Purpura • IL10

Spatial transcriptomics reveals atorvastatin modulates the tumor microenvironment to suppress breast cancer liver metastatic outgrowth. (PubMed, Neoplasia) - "DEG analysis revealed coordinated downregulation of metastasis and extracellular matrix- associated transcripts in atorvastatin-treated TAFs. Our findings suggest that atorvastatin alters the cellular milieu in the disseminated microenvironment towards one in which pro-tumorigenic CAF and HSC populations are reduced, to create a microenvironmental niche favorable for maintaining metastatic dormancy and preventing relapse."

Biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • CAFs • CXCL8 • LRRC1 • SPP1

A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes. (PubMed, Front Pharmacol) - "The activities of CYP3A and transporters P-gp, OATP and BCRP were evaluated in type 2 diabetes patients and healthy volunteers (HVs) following a single oral dose of five probe drugs (midazolam, dabigatran etexilate, pitavastatin, rosuvastatin, and atorvastatin). Additionally, factors such as sex, BCRP genotype, and Clostridium_XlVb partly explained the IIV in probe drugs exposure. The findings regarding altered DMET activities and identified influence factors help to identify specific drug classes that may warrant closer clinical attention in type 2 diabetes patients."

Journal • PK/PD data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The association between atorvastatin use and prothrombin time, apolipoprotein A-I levels, and apolipoprotein B levels in patients with type 2 diabetes mellitus and no history of atherosclerotic cardiovascular diseases: a cross-sectional study. (PubMed, Postgrad Med) - "No significant association was observed between PT and ApoA-I. The inverse association between PT and ApoB may suggest a potential link between the reduction in ApoB levels, through atorvastatin use, and the modulation of coagulation pathways relevant to venous thrombosis, although this requires confirmation in future prospective studies."

Journal • Observational data • Atherosclerosis • Cardiovascular • Diabetes • Hematological Disorders • Metabolic Disorders • Thrombosis • Type 2 Diabetes Mellitus • APOA1 • APOB

Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials. (PubMed, BMC Cardiovasc Disord) - "Rosuvastatin showed a modest but statistically significant advantage over atorvastatin in lowering CRP, especially in patients with higher baseline inflammation or hypertension. Evidence for other biomarkers remains inconclusive. Tailoring statin therapy to patient profiles may optimize benefits."

Biomarker • Clinical • Head-to-Head • Journal • Retrospective data • Review • Cardiovascular • Hypertension • Oncology • CRP • IL6 • TNFA